Back

New GLP-1 Clinical Study Finds Calocurb® Reduces Body Weight and Body Fat Without Loss of Muscle Mass

Calocurb

The natural GLP-1 activator is clinically shown to support fat loss, including visceral fat reduction, while preserving lean muscle

AUCKLAND, New Zealand--BUSINESS WIRE--

Calocurb, the New Zealand-based company bringing the world the first 100% natural GLP-1 activator, announces today the publication of a new clinical study in US medical journal, Obesity Pillars, demonstrating Calocurb’s effectiveness in weight loss and muscle preservation. In the brand’s fourth human clinical study users saw an average weight loss of 8.3 lbs (3.77 kg) after six months of consistent use paired with ‘real world’ healthy diet and exercise advice. There was no loss in muscle mass.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260723541082/en/

Calocurb is derived from a patented bitter hops extract called Amarasate®, first identified as part of an extensive research programme funded by the New Zealand government. Unlike prescription GLP-1 medications, Calocurb works by significantly stimulating 3 of the body’s own natural satiety hormones (GLP-1, CCK, PYY) by activating bitter taste receptors in the L-cells of the gastrointestinal tract, to reduce hunger, cravings and calorie intake.

The randomized, double-blind clinical trial undertaken by a research institute of the New Zealand government, evaluated Calocurb over 24 weeks with a three-month follow-up on all participants. Those who took Calocurb experienced significantly greater reductions in body weight, body fat, and visceral fat, and also maintained muscle mass, compared to the placebo group. This is a major feat in the weight management space, as synthetic GLP-1 medications have been shown to decrease muscle mass, potentially leading to long-term issues with mobility and bone health. Key results from Calocurb’s fourth human clinical study include the following:

• Calocurb is clinically shown to improve body composition by reducing body fat without losing muscle mass
  • Average weight loss of 8.3 lbs (3.77 kg) after six months, compared to 0.88 lbs (0.4 kg) with the placebo group
• Over 6.5x greater reduction in body fat vs placebo
  • Average body fat loss of 9.9 lbs (4.49 kg) vs 1.5 lbs (0.68 kg) after six months of consistent use of Calocurb vs placebo
• 3.5x greater reduction in visceral fat vs placebo
  • Average visceral fat loss of 5 in² (32.5 cm2) vs 1.4 in² (9.1 cm2) lost after six months of consistent use of Calocurb vs placebo

For over a decade, Calocurb has undertaken ground-breaking clinical research into Amarasate® to continue bringing natural weight management solutions to those interested in GLP-1 and weight loss options.

“The new clinical data proves not only Calocurb’s contribution to weight loss overall, but also muscle preservation, which is groundbreaking in the crowded space of GLP-1s and other weight reduction options,” said Sarah Kennedy, Founder and CEO of Calocurb. “From our years of research, we knew Calocurb was life-changing for so many, but now we are very excited to present independent clinical data to show its effectiveness across the board to improve body composition, while being 100% natural.”

As the world's first natural GLP-1 option clinically proven to facilitate weight loss, Calocurb opens new doors for individuals on a weight management journey. Rooted in overall wellness, science, and effectiveness, these new strides will equip practitioners, patients, and consumers with the tools and knowledge to build a healthier population.

About Calocurb® and Amarasate®

Amarasate® is a natural extract from a specific New Zealand bitter hop and is the active ingredient in Calocurb®, which has been demonstrated in 3 previous, published, human clinical trials to activate endogenous GLP-1, CCK and PYY release and reduce appetite by 30%, cravings by 40%, and caloric intake by an average of 18% in one hour. Calocurb is a non-prescription capsule taken on an empty stomach twice a day. The capsule releases in the small intestine and super-stimulates the body’s own GLP-1, CCK and PYY when Amarasate® interacts with bitter taste receptors, or TAS2Rs, in the small intestine. This activates satiety hormones that send a signal to the appetite center in the brain communicating its feeling fuller before eating which results in behavioral change. All three hormones support satiety, while CCK promotes fat oxidation and PYY supports muscle preservation. Together, this triple hormone activation improves body composition through weight loss, fat loss, and muscle preservation. Calocurb, at $89.99 for a month’s supply, is an affordable solution for those wanting a proven, natural solution to weight health, and for those coming off GLP-1 injectables to maintain weight lost. Calocurb is used extensively in the US by both practitioners and consumers.

Additional NEW study data: Table 1: Mean changes in body weight and composition: Calocurb vs placebo at 24 weeks
	Parameter	Calocurb (n=65)			Placebo (n=63)
	Change in body weight (lb and kg)	-8.4 lbs or -3.8 kg			-0.9 lbs or -0.4 kg
	Change in body weight (%)	-4.3			-0.5
	Change in fat mass (lb and kg)	-9.9 lbs or -4.5 kg			-1.5 lbs or -0.7 kg
	Change in visceral fat area (in2 and cm2)	-5.04 in2 or -32.5 cm2			-1.39 in2 or -9.1 cm2
	Change in muscle mass (lb and kg)	+1.9 lbs or +0.9 kg			+0.44 lbs or +0.2 kg
	Change in muscle mass-adjusted body weight (%)	-5.3			-0.7
	* all between group differences were significant (p<0.05 except for the change in muscle mass, which was not significantly different

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260723541082/en/

Contact details:

Catie Currie
[email protected]